Ascendis Pharma A (ASND) Gross Profit (2021 - 2026)

Ascendis Pharma A (ASND) has 6 years of Gross Profit data on file, last reported at $268.2 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 205.59% year-over-year to $268.2 million; the trailing twelve-month figure through Mar 2026 stood at $895.8 million (up 166.39% YoY), and the FY2025 full-year result was $727.8 million, up 86.78% from the prior year.
• Gross Profit advanced to $268.2 million in Q1 2026, from $260.6 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $268.2 million in Q1 2026 to a low of $2.9 million in Q1 2022.
• A 5-year average of $94.6 million and a median of $51.2 million in 2024 frame the typical range for Gross Profit.
• Across the five-year window, Gross Profit soared 1054.34% in 2022 and dropped 29.6% in 2024, its largest moves.
• Tracing ASND's Gross Profit over 5 years: stood at $18.1 million in 2022, then soared by 601.2% to $127.2 million in 2023, then soared by 34.3% to $170.9 million in 2024, then jumped by 52.54% to $260.6 million in 2025, then advanced by 2.9% to $268.2 million in 2026.
• Business Quant data shows ASND's Gross Profit at $268.2 million in Q1 2026, $260.6 million in Q4 2025, and $223.6 million in Q3 2025.